In the CKD milieu, FGF23 induces cardiac hypertrophy that is accompanied by pathologic alterations, while by itself FGF23/FGFR4 signaling causes hypertrophy that might be beneficial. Here, FGFR4 is linked to cardiac hypertrophy.